Sensor longevity breakthrough in Lifecare
Ongoing clinical development study confirms Lifecare’s expectation of a sensor longevity that far exceeds the lifetime of existing and commercially available needle sensors for glucose monitoring.
CSO Prof. Andreas Pfützner and CEO Joacim Holter
Today Lifecare can report that sensors used in a three-day clinical study continue to work in an in vitro set up, showing an operational longevity for a total of 4 weeks and still ongoing.
The current clinical trial sensor is not the final product, but it already represents a major step forward for Lifecare’s Sencell-technology. – We have 20 people in our outstanding team who have worked intensively to achieve these results and everyone is thrilled to see the outcome, says CEO Joacim Holter.
Lifecare is developing a Continuous Glucose Monitoring (CGM) sensor at the size of a grain of rice, with an expected longevity exceeding those of existing needle based CGM-systems. Lifecares sensor is currently subject to the first-in-human studies.
Lifecare CSO Prof. Andreas Pfützner describes the results as a breakthrough for the product development of the sensor technology. – Now we have a first proof that a sensor employing the miniaturized core Sencell technology has been operational in the human body for several days continues to work in an in vitro set-up for more than 4 weeks. This is not possible with a commercially available needle sensor. The in vitro set-up experiment will continue, with the expectation that we can confirm additional longevity in the months to follow.
– Beside the longevity, the study provides already strong indications that our technology is at least as accurate and may be superior to commercially available needle sensors. Our study is also an indication of the robustness of the sensing technology – you can basically take the sensor in and out of the body and it continues to measure correctly, says Prof. Pfützner .
According to the CSO the study shows the stability and robustness of Lifecare’s technology, and it is an indication that the medtech company is in the process of reaching the planned long term of longevity.
– As previously communicated, we have prolonged our technology development study to clear out issues, improve the product, improve the performance of the product, and improve the longevity of the product, summarizes Joacim Holter.
The current status of the development study firmly confirms the groundbreaking potential of the Sencell technology.
For more information: CEO Joacim Holter, firstname.lastname@example.org , +47 400 59 040